Universe Pharmaceuticals (UPC) Competitors

$3.00 +0.18 (+6.38%)

Closing price 05/7/2026 04:00 PM Eastern

Extended Trading

$2.83 -0.17 (-5.67%)

As of 07:17 AM Eastern

UPC vs. RNAZ, BCLI, GRTX, BCAB, and GELS

Should you be buying Universe Pharmaceuticals stock or one of its competitors? The main competitors of Universe Pharmaceuticals include TransCode Therapeutics (RNAZ), Brainstorm Cell Therapeutics (BCLI), Galera Therapeutics (GRTX), BioAtla (BCAB), and Gelteq (GELS). These companies are all part of the "pharmaceutical products" industry.

How does Universe Pharmaceuticals compare to TransCode Therapeutics?

Universe Pharmaceuticals (NASDAQ:UPC) and TransCode Therapeutics (NASDAQ:RNAZ) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, earnings, valuation, media sentiment, analyst recommendations, institutional ownership and profitability.

: Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Universe Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00
TransCode Therapeutics
1 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00
: In the previous week, Universe Pharmaceuticals' average media sentiment score of 0.00 equaled TransCode Therapeutics'average media sentiment score.
Company Overall Sentiment
Universe Pharmaceuticals Neutral
TransCode Therapeutics Neutral
: 0.2% of Universe Pharmaceuticals shares are held by institutional investors. 57.4% of Universe Pharmaceuticals shares are held by insiders. Comparatively, 0.0% of TransCode Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
: Universe Pharmaceuticals has a beta of 1.58, suggesting that its share price is 58% more volatile than the S&P 500. Comparatively, TransCode Therapeutics has a beta of 1.39, suggesting that its share price is 39% more volatile than the S&P 500.
: Universe Pharmaceuticals' return on equity of 0.00% beat TransCode Therapeutics' return on equity.
Company Net Margins Return on Equity Return on Assets
Universe Pharmaceuticals N/A N/A N/A
TransCode Therapeutics N/A -382.87% -57.10%
: Universe Pharmaceuticals has higher revenue and earnings than TransCode Therapeutics.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Universe Pharmaceuticals $17.86M 0.09 -$3.67M N/A N/A
TransCode Therapeutics N/A N/A -$34.66M -$99.36 N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Universe Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
TransCode Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Company	Overall Sentiment
Universe Pharmaceuticals	Neutral
TransCode Therapeutics	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Universe Pharmaceuticals	N/A	N/A	N/A
TransCode Therapeutics	N/A	-382.87%	-57.10%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Universe Pharmaceuticals	$17.86M	0.09	-$3.67M	N/A	N/A
TransCode Therapeutics	N/A	N/A	-$34.66M	-$99.36	N/A

Summary

Universe Pharmaceuticals beats TransCode Therapeutics on 7 of the 7 factors compared between the two stocks.

How does Universe Pharmaceuticals compare to Brainstorm Cell Therapeutics?

Universe Pharmaceuticals (NASDAQ:UPC) and Brainstorm Cell Therapeutics (NASDAQ:BCLI) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, earnings, valuation, profitability, dividends, institutional ownership, analyst recommendations and media sentiment.

: Universe Pharmaceuticals has higher revenue and earnings than Brainstorm Cell Therapeutics.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Universe Pharmaceuticals $17.86M 0.09 -$3.67M N/A N/A
Brainstorm Cell Therapeutics N/A N/A -$11.62M -$1.90 N/A
: Company Net Margins Return on Equity Return on Assets
Universe Pharmaceuticals N/A N/A N/A
Brainstorm Cell Therapeutics N/A N/A -519.50%
: 0.2% of Universe Pharmaceuticals shares are owned by institutional investors. Comparatively, 14.3% of Brainstorm Cell Therapeutics shares are owned by institutional investors. 57.4% of Universe Pharmaceuticals shares are owned by company insiders. Comparatively, 11.2% of Brainstorm Cell Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
: In the previous week, Brainstorm Cell Therapeutics had 1 more articles in the media than Universe Pharmaceuticals. MarketBeat recorded 1 mentions for Brainstorm Cell Therapeutics and 0 mentions for Universe Pharmaceuticals. Universe Pharmaceuticals' average media sentiment score of 0.00 equaled Brainstorm Cell Therapeutics'average media sentiment score.
Company Overall Sentiment
Universe Pharmaceuticals Neutral
Brainstorm Cell Therapeutics Neutral
: Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Universe Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00
Brainstorm Cell Therapeutics
0 Sell rating(s)

1 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
2.00
: Universe Pharmaceuticals has a beta of 1.58, suggesting that its stock price is 58% more volatile than the S&P 500. Comparatively, Brainstorm Cell Therapeutics has a beta of 0.22, suggesting that its stock price is 78% less volatile than the S&P 500.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Universe Pharmaceuticals	$17.86M	0.09	-$3.67M	N/A	N/A
Brainstorm Cell Therapeutics	N/A	N/A	-$11.62M	-$1.90	N/A

Company	Net Margins	Return on Equity	Return on Assets
Universe Pharmaceuticals	N/A	N/A	N/A
Brainstorm Cell Therapeutics	N/A	N/A	-519.50%

Company	Overall Sentiment
Universe Pharmaceuticals	Neutral
Brainstorm Cell Therapeutics	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Universe Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Brainstorm Cell Therapeutics	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Universe Pharmaceuticals beats Brainstorm Cell Therapeutics on 5 of the 8 factors compared between the two stocks.

How does Universe Pharmaceuticals compare to Galera Therapeutics?

Universe Pharmaceuticals (NASDAQ:UPC) and Galera Therapeutics (NASDAQ:GRTX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, earnings, valuation, profitability, dividends, institutional ownership, analyst recommendations and media sentiment.

: In the previous week, Universe Pharmaceuticals' average media sentiment score of 0.00 equaled Galera Therapeutics'average media sentiment score.
Company Overall Sentiment
Universe Pharmaceuticals Neutral
Galera Therapeutics Neutral
: Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Universe Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00
Galera Therapeutics
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
: 0.2% of Universe Pharmaceuticals shares are owned by institutional investors. Comparatively, 50.8% of Galera Therapeutics shares are owned by institutional investors. 57.4% of Universe Pharmaceuticals shares are owned by company insiders. Comparatively, 12.9% of Galera Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
: Universe Pharmaceuticals has higher revenue and earnings than Galera Therapeutics.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Universe Pharmaceuticals $17.86M 0.09 -$3.67M N/A N/A
Galera Therapeutics N/A N/A -$59.08M $0.64 0.16
: Company Net Margins Return on Equity Return on Assets
Universe Pharmaceuticals N/A N/A N/A
Galera Therapeutics N/A N/A -99.34%
: Universe Pharmaceuticals has a beta of 1.58, suggesting that its stock price is 58% more volatile than the S&P 500. Comparatively, Galera Therapeutics has a beta of 2.64, suggesting that its stock price is 164% more volatile than the S&P 500.

Company	Overall Sentiment
Universe Pharmaceuticals	Neutral
Galera Therapeutics	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Universe Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Galera Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Universe Pharmaceuticals	$17.86M	0.09	-$3.67M	N/A	N/A
Galera Therapeutics	N/A	N/A	-$59.08M	$0.64	0.16

Company	Net Margins	Return on Equity	Return on Assets
Universe Pharmaceuticals	N/A	N/A	N/A
Galera Therapeutics	N/A	N/A	-99.34%

Summary

Universe Pharmaceuticals beats Galera Therapeutics on 5 of the 7 factors compared between the two stocks.

How does Universe Pharmaceuticals compare to BioAtla?

BioAtla (NASDAQ:BCAB) and Universe Pharmaceuticals (NASDAQ:UPC) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, dividends, risk, media sentiment, institutional ownership, earnings, profitability and analyst recommendations.

: Company Net Margins Return on Equity Return on Assets
BioAtla N/A N/A -257.22%
Universe Pharmaceuticals N/A N/A N/A
: In the previous week, BioAtla's average media sentiment score of 0.00 equaled Universe Pharmaceuticals'average media sentiment score.
Company Overall Sentiment
BioAtla Neutral
Universe Pharmaceuticals Neutral
: BioAtla currently has a consensus target price of $200.00, suggesting a potential upside of 4,497.70%. Given BioAtla's stronger consensus rating and higher probable upside, analysts plainly believe BioAtla is more favorable than Universe Pharmaceuticals.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BioAtla
1 Sell rating(s)
1 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
2.00
Universe Pharmaceuticals
1 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00
: Universe Pharmaceuticals has higher revenue and earnings than BioAtla.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
BioAtla $2M 3.61 -$59.61M -$50.50 N/A
Universe Pharmaceuticals $17.86M 0.09 -$3.67M N/A N/A
: 77.2% of BioAtla shares are held by institutional investors. Comparatively, 0.2% of Universe Pharmaceuticals shares are held by institutional investors. 11.8% of BioAtla shares are held by insiders. Comparatively, 57.4% of Universe Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
: BioAtla has a beta of 0.81, suggesting that its stock price is 19% less volatile than the S&P 500. Comparatively, Universe Pharmaceuticals has a beta of 1.58, suggesting that its stock price is 58% more volatile than the S&P 500.

Company	Net Margins	Return on Equity	Return on Assets
BioAtla	N/A	N/A	-257.22%
Universe Pharmaceuticals	N/A	N/A	N/A

Company	Overall Sentiment
BioAtla	Neutral
Universe Pharmaceuticals	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioAtla	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Universe Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioAtla	$2M	3.61	-$59.61M	-$50.50	N/A
Universe Pharmaceuticals	$17.86M	0.09	-$3.67M	N/A	N/A

Summary

BioAtla and Universe Pharmaceuticals tied by winning 5 of the 10 factors compared between the two stocks.

How does Universe Pharmaceuticals compare to Gelteq?

Gelteq (NASDAQ:GELS) and Universe Pharmaceuticals (NASDAQ:UPC) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, media sentiment, valuation, institutional ownership, earnings, profitability, risk and analyst recommendations.

: Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Gelteq
1 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00
Universe Pharmaceuticals
1 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00
: Universe Pharmaceuticals has higher revenue and earnings than Gelteq.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Gelteq $110K 45.37 -$4.30M N/A N/A
Universe Pharmaceuticals $17.86M 0.09 -$3.67M N/A N/A
: Gelteq has a beta of 0.06, suggesting that its share price is 94% less volatile than the S&P 500. Comparatively, Universe Pharmaceuticals has a beta of 1.58, suggesting that its share price is 58% more volatile than the S&P 500.
: 0.2% of Universe Pharmaceuticals shares are held by institutional investors. 57.4% of Universe Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
: Company Net Margins Return on Equity Return on Assets
Gelteq N/A N/A N/A
Universe Pharmaceuticals N/A N/A N/A
: In the previous week, Gelteq had 1 more articles in the media than Universe Pharmaceuticals. MarketBeat recorded 1 mentions for Gelteq and 0 mentions for Universe Pharmaceuticals. Gelteq's average media sentiment score of 0.00 equaled Universe Pharmaceuticals'average media sentiment score.
Company Overall Sentiment
Gelteq Neutral
Universe Pharmaceuticals Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gelteq	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Universe Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gelteq	$110K	45.37	-$4.30M	N/A	N/A
Universe Pharmaceuticals	$17.86M	0.09	-$3.67M	N/A	N/A

Company	Net Margins	Return on Equity	Return on Assets
Gelteq	N/A	N/A	N/A
Universe Pharmaceuticals	N/A	N/A	N/A

Company	Overall Sentiment
Gelteq	Neutral
Universe Pharmaceuticals	Neutral

Summary

Universe Pharmaceuticals beats Gelteq on 5 of the 7 factors compared between the two stocks.

Get Universe Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding UPC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

UPC vs. The Competition

Export

Metric	Universe Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.59M	$3.17B	$6.30B	$12.14B
Dividend Yield	N/A	1.87%	2.78%	5.24%
P/E Ratio	N/A	17.52	28.45	27.00
Price / Sales	0.09	301.91	534.76	76.45
Price / Cash	N/A	56.30	43.30	53.97
Price / Book	0.03	4.31	9.83	6.89
Net Income	-$3.67M	$72.19M	$3.55B	$333.11M
7 Day Performance	N/A	N/A	N/A	0.14%
1 Month Performance	-4.76%	4.32%	5.22%	6.78%
1 Year Performance	N/A	46.57%	40.39%	38.93%

Universe Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
UPC Universe Pharmaceuticals	0.106 of 5 stars	$3.00 +6.4%	N/A	N/A	$1.59M	$17.86M	N/A	220
RNAZ TransCode Therapeutics	0.0609 of 5 stars	$7.74 -1.1%	N/A	-23.1%	$7.18M	N/A	N/A	9
BCLI Brainstorm Cell Therapeutics	0.1231 of 5 stars	$0.65 -1.1%	N/A	-42.4%	$7.17M	N/A	N/A	40	News Coverage Upcoming Earnings Gap Down
GRTX Galera Therapeutics	N/A	$0.09 +4.8%	N/A	+336.7%	$7.11M	N/A	N/A	30	Upcoming Earnings Gap Up
BCAB BioAtla	1.8446 of 5 stars	$4.70 +10.1%	$200.00 +4,155.3%	-80.5%	$7.08M	$2M	N/A	60	Positive News Upcoming Earnings Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:UPC) was last updated on 5/8/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Universe Pharmaceuticals (UPC) Competitors

UPC vs. RNAZ, BCLI, GRTX, BCAB, and GELS

How does Universe Pharmaceuticals compare to TransCode Therapeutics?

Summary

How does Universe Pharmaceuticals compare to Brainstorm Cell Therapeutics?

Summary

How does Universe Pharmaceuticals compare to Galera Therapeutics?

Summary

How does Universe Pharmaceuticals compare to BioAtla?

Summary

How does Universe Pharmaceuticals compare to Gelteq?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

UPC vs. The Competition

Universe Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Universe Pharmaceuticals (UPC) Competitors

UPC vs. RNAZ, BCLI, GRTX, BCAB, and GELS

How does Universe Pharmaceuticals compare to TransCode Therapeutics?

Summary

How does Universe Pharmaceuticals compare to Brainstorm Cell Therapeutics?

Summary

How does Universe Pharmaceuticals compare to Galera Therapeutics?

Summary

How does Universe Pharmaceuticals compare to BioAtla?

Summary

How does Universe Pharmaceuticals compare to Gelteq?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

UPC vs. The Competition

Universe Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools